Fathers Play a Big Role in Childhood Obesity Risk

When discussing childhood obesity, most conversations focus on mothers’ health during pregnancy and early childhood. However, emerging research suggests that fathers may have a significant influence on a child’s future weight and metabolic health long before conception even occurs.

A recent review published in Current Obesity Reports highlights the growing evidence that fathers contribute to obesity risk across generations through biological, behavioral, and environmental factors. The findings suggest that efforts to prevent childhood obesity may be more effective when both parents, not just mothers, are included in research, education, and intervention programs.

Research has consistently shown that children are more likely to develop obesity if one or both parents are affected. The risk becomes even greater when both parents have obesity. While genetics play a role, scientists now recognize that obesity is influenced by a complex combination of inherited traits, lifestyle habits, family behaviors, and environmental factors.

How do fathers influence health before conception?

Traditionally, scientists have focused on how maternal health affects a developing baby. The concept known as the Developmental Origins of Health and Disease (DOHaD) emphasizes that conditions around conception and pregnancy can shape a child’s lifelong health.

More recently, researchers have expanded this framework to include fathers through the Paternal Origins of Health and Disease (POHaD) model. This approach recognizes that a father’s health before conception may also affect a child’s future risk of obesity and metabolic disease.

According to the review, paternal obesity can influence offspring health through changes in sperm quality and function. Excess body weight in men has been linked to lower sperm concentration, reduced sperm movement, and increased DNA damage within sperm cells. These changes are thought to result from obesity-related disruptions in hormone regulation, inflammation, and metabolic function.

Researchers estimate that men with obesity face a 30% to 66% greater risk of infertility compared to men of healthier weight. Obesity has also been associated with an increased risk of pregnancy loss that cannot be explained by maternal factors alone.

Epigenetics may help explain the connection

Beyond genetics, researchers are investigating how epigenetic changes may influence obesity risk across generations. Epigenetics refers to modifications that affect how genes are expressed without altering the underlying DNA sequence. Obesity has been linked to changes in the epigenetic markers, and some of these alterations may be passed to future offspring.

Scientists believe these changes could affect biological pathways involved in appetite control, insulin function, and fat storage. Animal studies have shown that fathers consuming high-fat diets can pass obesity-related metabolic changes to their offspring.

While researchers are still working to fully understand these mechanisms in humans, one encouraging finding is that some obesity-related epigenetic changes appear to be reversible. Improvements in diet, exercise, and overall health before conception may help reduce potential risks.

Fathers also shape family health habits

A father’s influence extends well beyond biology. Research shows that fatherhood often brings changes in weight and lifestyle habits, and poor dietary habits may negatively affect reproductive health.

After a child is born, fathers continue to influence obesity risk through everyday behaviors and parenting practices. Children frequently model the habits they observe at home. Fathers who prioritize nutritious meals, regular exercise, and active lifestyles can help establish healthy routines for their children. Likewise, fathers who spend more time being sedentary or consuming unhealthy foods may unintentionally reinforce similar behaviors.

Environment and neighborhood matter too

The review emphasizes that obesity risk is not solely determined by individual choices. Social and environmental factors can strongly influence health outcomes for both fathers and children.

Income, education, neighborhood conditions, and food access all affect obesity risk. Families living in areas with limited access to affordable, nutritious foods may rely more heavily on calorie-dense processed foods. Food insecurity has been linked to higher obesity rates in both adults and children.

Access to safe parks, playgrounds, and recreational spaces can also influence physical activity levels. When opportunities for exercise are limited, sedentary behavior often increases.

… As does mental health

The review notes that fathers experiencing depression may be less likely to engage in positive parenting behaviors or prioritize preventive healthcare for themselves and their families. This can affect household routines related to nutrition, sleep, and physical activity.

Children who grow up in homes where a parent struggles with depression may also face a greater risk of adverse childhood experiences, which have been associated with long-term health challenges, including obesity.

Finally, the findings suggest that childhood obesity prevention should begin earlier than many people realize and should involve fathers from the start. This means including fathers in preconception counseling, pregnancy education programs, and family-based obesity prevention efforts.

Your responses and feedback are welcome!

Source: “Fathers shape childhood obesity risk long before birth,” News-Medical.net, 6/9/26
Source: “The Role of Fathers in the Intergenerational Transmission of Obesity,” Current Obesity Reports, 5/26/26
Image by Towfiqu barbhuiya/Pexels

Studies Suggest GLP-1 Medications May Help Slow Progression of Some Cancers

GLP-1 medications have become widely known for their role in treating type 2 diabetes and supporting weight loss. Now, emerging research suggests these drugs may offer another important benefit: helping slow the progression of certain obesity-related cancers, as well as breast cancer.

A new study presented at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) found that patients taking GLP-1 receptor agonists after a cancer diagnosis experienced significantly lower rates of cancer progression and death compared to patients taking other diabetes medications.

GLP-1 receptor agonists, which include medications commonly prescribed for diabetes and obesity management, have attracted growing scientific interest in recent years. Researchers have increasingly explored whether the drugs’ effects extend beyond controlling blood sugar and promoting weight loss.

According to Dr. Marcin Chwistek, chief of supportive oncology and palliative care at Fox Chase Cancer Center and an ASCO expert in supportive care, GLP-1 medications may influence several biological pathways linked to cancer development and progression. Researchers believe the drugs’ anti-inflammatory and immune-regulating effects could play a role in improving outcomes for cancer patients.

What the studies found

The research team analyzed health records from more than 12,000 patients diagnosed with one of seven obesity-related cancers at stages 1, 2, or 3. The investigators compared patients who began taking GLP-1 medications after their cancer diagnosis with similar patients who were treated with a different class of diabetes drugs known as DPP-4 inhibitors, or gliptins.

The results were notable. Patients using GLP-1 medications showed a meaningful reduction in cancer progression across several solid tumor types. The strongest benefits were observed among patients with lung, breast, colon, and liver cancers. In these groups, patients taking GLP-1 drugs were approximately 38% to 50% less likely to develop stage 4 or metastatic disease compared with those receiving alternative diabetes treatments.

The study also found that GLP-1 use was associated with a 33% lower risk of death from any cause. Among all cancer types examined, breast cancer patients appeared to experience the greatest survival benefit. Researchers reported that GLP-1 users with breast cancer had a 45% lower risk of death compared to similar patients taking other diabetes medications.

These findings suggest that the medications may have an impact not only on cancer progression but also on overall survival.

Scientists are still working to understand the mechanisms behind these results. One possibility is that GLP-1 medications help reduce chronic inflammation, which has long been linked to both obesity and cancer development. Inflammation can create an environment that supports tumor growth and spread.

Researchers also point to the drugs’ effects on the immune system. By influencing immune responses, GLP-1 medications may help the body better control cancer progression.

Weight loss itself may also contribute to improved outcomes, since excess body weight is a known risk factor for several types of cancer. However, additional research will be needed to determine exactly how these medications may influence cancer biology.

The study has been presented at ASCO’s annual meeting but has not yet been published in a peer-reviewed medical journal. Research presented at scientific conferences often undergoes additional review and validation before becoming part of standard medical practice.

Another study found that women who used GLP-1 medications had a significantly lower risk of developing breast cancer than those who did not use the drugs. The study reviewed health data from more than 110,000 women ages 45 to 80 and found that GLP-1 users were about 30% less likely to be diagnosed with breast cancer. The findings were also presented at the 2026 ASCO annual meeting by Dr. Elizabeth McDonald of the University of Pennsylvania’s Perelman School of Medicine and were simultaneously published in JCO Oncology Practice.

Dr. McDonald said:

GLP-1 medications are intriguing from a cancer research perspective because they weren’t designed for cancer therapy, but they do affect many different targets and pathways associated with cancer development, so we’re eager to study them in this context.

Your responses and feedback are welcome!

Source: “GLP-1 Meds May Help Slow the Spread of Certain Obesity-Related Cancers,” HealthDay, 5/27/26
Source: “GLP-1s May Reduce Metastatic Progression of Certain Obesity-Related Cancers,” ASCO, 5/21/26
Source: “GLP-1 use linked to lower breast cancer incidence in large cohort study,” PennMedicine.org, 6/2/26
Source: “GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women,” JCO Oncology Practice, 6/2/26
Image by Darina Belonogova/Pexels

Early-Life Junk Food Rewires the Brain

A growing body of research continues to show that what children eat can have lifelong consequences. Now, a new study published in Nature Communications suggests that eating a high-fat, high-sugar junk food diet during early life may permanently alter the brain’s appetite and reward systems, increasing the risk of overeating well into adulthood. The findings offer new insight into how childhood nutrition affects long-term health and reveal that the gut microbiome may hold the key to reversing some of the damage.

Researchers investigated how consuming a high-fat, high-sugar diet early in life impacts eating behaviors later on, even after switching to a healthier diet in adulthood. The study found that early exposure to junk food can leave a lasting imprint on the brain, essentially rewiring hunger and reward pathways in ways that persist over time.

Perhaps most concerning, the changes remained even after the subjects returned to a healthy weight and healthier eating patterns. This suggests that the effects of poor childhood nutrition go beyond temporary weight gain and may fundamentally influence how the brain regulates appetite.

One of the study’s most striking discoveries was that males and females responded differently to the unhealthy diet. Researchers found that females appeared to be more vulnerable to the long-term effects of junk food consumption. In females, the diet reduced leptin receptors in the brain.

Leptin is a hormone responsible for signaling fullness and helping regulate food intake. When leptin signaling is disrupted, the brain may struggle to recognize when enough food has been consumed, increasing the likelihood of overeating.

The unhealthy diet also interfered with how females processed essential amino acids such as tryptophan and arginine, which play important roles in mood, metabolism, and brain function. Males, on the other hand, experienced disruptions in immune-sensing pathways and steroid metabolism, showing that junk food can affect biological systems differently depending on sex. These findings may help researchers better understand why some individuals are more susceptible to obesity and eating disorders later in life.

While the long-term brain changes linked to junk food are concerning, the study also uncovered a promising possibility: targeted gut microbiome therapies may help reverse some of the damage. Researchers successfully used both probiotics and prebiotics to improve eating behaviors and restore gut-brain communication pathways.

Probiotics, including Bifidobacterium longum, appeared to directly reduce overeating behaviors while causing minimal disruption to the existing gut ecosystem. Meanwhile, prebiotics helped improve the overall gut environment and supported healthier communication between the gut and the brain.

The findings reinforce the growing understanding that the gut microbiome plays a major role in mental and physical health. Often referred to as the “gut-brain axis,” this communication network connects digestive health with brain function, appetite regulation, mood, and metabolism. Researchers suggest that targeting the microbiome could potentially serve as a “reset button” for unhealthy eating patterns that begin in childhood.

There are several reasons why limiting junk food during childhood is so important. One is nutritional deficiencies. Children require vitamins, minerals, protein, fiber, and healthy fats to support proper physical and cognitive development. Diets dominated by processed foods often fail to provide these essential nutrients, potentially impacting growth, immunity, and brain development.

Another reason is the increased risk of weight gain and obesity. Then there are effects on learning and behavior, as research has linked diets high in sugar and unhealthy fats with poorer concentration, mood swings, and behavioral difficulties in children. Let’s not forget dental health problems. Sugary snacks and beverages can increase the risk of cavities and tooth decay. Since children’s teeth are still developing, frequent exposure to sugary foods can have lasting consequences for oral health.

Finally, children who regularly consume junk food may become less interested in healthier options like fruits, vegetables, whole grains, and lean proteins. These habits can continue into adulthood, increasing the risk of chronic disease over time.

As scientists continue exploring the connection between nutrition, the gut, and the brain, one message is becoming increasingly clear: What children eat today may influence their health and eating behaviors for decades to come.

Your responses and feedback are welcome!

Source: “Childhood Junk Food May Rewire The Brain For Life, Reveals Study,” NDTV.com, 5/28/26
Source: “Bifidobacterium longum and prebiotic interventions restore early-life high-fat/high-sugar diet-induced alterations in feeding behavior in adult mice,” Nature Communications, 2/24/26
Source: New Study Discovers That a Junk-Food Diet Rewires the Brain,” Inc.com, 5/24/26
Image by Tara Winstead/Pexels

Rethinking the “Adiposity Rebound”

For decades, doctors and researchers have relied on a concept known as the “adiposity rebound” to help explain childhood growth patterns and predict future obesity risk. But new research is now challenging that long-standing belief, suggesting that the rise in body mass index (BMI) seen in early childhood may have far less to do with body fat than previously thought.

The findings, presented by Andrew Agbaje at the European Congress on Obesity and published in The Journal of Nutrition, argue that the so-called adiposity rebound may actually reflect healthy muscle and lean tissue development rather than an increase in fat mass.

What is the “adiposity rebound”?

The adiposity rebound theory dates back to 1984, when French researcher Marie Françoise Rolland-Cachera and colleagues described a predictable pattern in childhood BMI growth. Typically, BMI rises rapidly during infancy, declines through the preschool years, and then begins increasing again around ages 4 to 6. Researchers believed this second rise, the “rebound,” represented a return of body fat accumulation.

Over time, studies suggested that children who experienced this rebound earlier in life were more likely to develop obesity during adolescence and adulthood. As a result, the timing of adiposity rebound became widely discussed in pediatric health and obesity prevention. Many clinicians viewed an early rebound as a warning sign that could justify lifestyle interventions focused on diet, physical activity, and weight management.

Why researchers are questioning the theory

According to Prof. Agbaje, the problem may lie in relying too heavily on BMI as a measure of body fat. BMI is a simple calculation based on height and weight, but it cannot distinguish between fat, muscle, bone, and other lean tissues. This limitation has long been recognized in adults, especially among athletes or muscular people whose BMI may appear elevated despite having low body fat levels.

Dr. Agbaje argues that the same issue may exist in children. He says:

Puberty is a defining moment in human biology that alters the whole body, but adiposity rebound is not; it is a natural growth process unattached to any problem, whether it is early rebound or late. So the previous associations relating early BMI-based adiposity rebound to later life obesity are misleading analyses. Positive statistical associations do not always equate to biological plausibility.

New evidence points to lean mass growth

To explore what is really happening during early childhood growth, researchers examined data from 2,410 children and adolescents between ages 2 and 19 using information from the National Health and Nutrition Examination Survey (NHANES), dated 2021-2023.

Instead of focusing only on BMI, the study also analyzed waist circumference-to-height ratio (WHtR), which researchers say is a more accurate indicator of body fat distribution. The results showed a striking difference between BMI patterns and WHtR patterns.

While BMI followed the familiar trajectory, declining in early childhood before increasing again, WHtR continued to decrease for several years and never returned to the higher levels seen during toddlerhood. Researchers say this finding suggests that the BMI rebound is not actually driven by increasing fat mass. Instead, it may reflect healthy gains in muscle, lean tissue, and overall body development.

In other words, what many experts once viewed as a warning sign of obesity could actually represent a normal and beneficial stage of growth.

A “body composition reset”

Dr. Agbaje describes this period as a kind of “body composition reset” that helps prepare children for later stages of development. Rather than indicating excess fat gain, the increase in BMI after early childhood may simply reflect the body building strength, muscle mass, and lean tissue needed for continued growth.

This interpretation could dramatically change how clinicians view childhood BMI trends. For years, some interventions attempted to delay or alter adiposity rebound in hopes of reducing future obesity risk. However, Dr. Agbaje points to long-term clinical trials that found dietary interventions did not change the timing or pattern of BMI rebound. That may be because the process is not a disease mechanism at all.

The study also adds to growing discussions about the limitations of BMI as a health tool. Researchers increasingly argue that BMI alone may oversimplify body composition, especially in children whose bodies are constantly developing.

Waist-to-height ratio, by contrast, may provide a clearer picture of unhealthy fat accumulation because it focuses more directly on central body fat. Dr. Agbaje believes WHtR could become a more useful screening tool for identifying excess fat in children and adolescents moving forward.

What this could mean for parents and pediatricians

The findings do not suggest that childhood obesity is unimportant or that healthy lifestyle habits should be ignored. Instead, the research highlights the importance of accurately understanding normal growth and avoiding unnecessary concern over biological processes that may simply reflect healthy development.

If future studies confirm these findings, it could reshape how pediatricians evaluate childhood growth patterns and obesity risk. Rather than treating early BMI rebounds as a condition requiring intervention, experts may begin focusing more on overall body composition, activity levels, nutrition quality, and long-term metabolic health.

Your responses and feedback are welcome!

Source: “Scientists Say a 40-Year-Old Childhood Obesity Warning May Be Completely Wrong,” SciTechDaily, 5/15/26
Source: “Early Adiposity Rebound and the Risk of Adult Obesity,” AAP.org, 3/1/98
Source: “Effects of 20-year infancy-onset dietary counselling on cardiometabolic risk factors in the Special Turku Coronary Risk Factor Intervention Project (STRIP): 6-year post-intervention follow-up,” The Lancet, May 2020
Source: “Waist-circumference-to-height-ratio had better longitudinal agreement with DEXA-measured fat mass than BMI in 7237 children,” Nature.com, 3/5/24
Source: “Adiposity Rebound or Fat-Free Mass Anabolism in Children—Challenging a 42-Year-Old BMI Puzzle with Waist-to-Height Ratio: The ASNF-NNF 2025 Inaugural Flemming Quaade Award for Innovation in Childhood Obesity Lecture,” The Journal of Nutrition, May 2026
Image by Los Muertos Crew/Pexels

CDC Updates Its Childhood Obesity Facts

Last week, the Centers for Disease Control and Prevention (CDC) released its childhood obesity facts, updated with some recent research data. While there are no shocking revelations to be glimpsed, especially by the readers of this blog, it’s always useful to try seeing the big picture backed up by reliable research. The numbers reveal a growing issue that touches nearly every part of society. No big surprise there, either. Here are some highlights (or, shall we say, lowlights).

Obesity in numbers

Between 2017 and March 2020, obesity affected 19.7% of children and adolescents in the United States. That translates to approximately 14.7 million young people between the ages of 2 and 19. For children, obesity is measured using Body Mass Index (BMI), with obesity defined as having a BMI at or above the 95th percentile for a child’s age and sex.

The climbing rates

One of the most concerning trends is how obesity rates increase as children get older. Among children ages 2 to 5, the obesity rate was 12.7%. However, the percentage climbed significantly among older age groups, reaching 20.7% for children ages 6 to 11 and 22.2% for adolescents ages 12 to 19. These statistics suggest that unhealthy habits and lifestyle challenges may intensify as children grow older, making early intervention especially important.

Racial and ethnic disparities

The data also highlights major disparities among racial and ethnic groups. Hispanic children experienced the highest obesity prevalence at 26.2%, followed closely by non-Hispanic Black children at 24.8%. In comparison, obesity rates were 16.6% among non-Hispanic white children and 9.0% among non-Hispanic Asian children. These differences point to broader social and environmental factors that can influence access to nutritious food, safe places to exercise, healthcare resources, and education about healthy living.

Obesity by gender

Gender differences also appear within these statistics. Among girls, obesity rates were highest in non-Hispanic Black girls, with nearly one-third affected. Among boys, Hispanic boys experienced the highest obesity prevalence at 29.3%. These patterns demonstrate that childhood obesity does not affect all groups equally and that targeted community-based solutions may be necessary.

Family income

Family income plays a significant role as well. Children from lower-income households were more likely to experience obesity than those from higher-income families. Obesity affected 25.8% of children living at or below 130% of the Federal Poverty Level, compared to just 11.5% of children from families earning more than 350% of the poverty level. Financial limitations can make it harder for families to purchase healthier foods, participate in recreational activities, or access preventive healthcare services.

Healthcare costs

Beyond the physical health concerns, childhood obesity also creates a major financial burden. Healthcare costs related to obesity among U.S. children reached an estimated $1.3 billion annually in 2019 dollars. On average, children with obesity incurred $116 more in medical expenses each year compared to children with healthy weight. For children with severe obesity, those costs rose to $310 more per year. These expenses reflect increased medical visits, treatments, and long-term health risks associated with obesity-related conditions.

It takes a village

Addressing childhood obesity requires a collaborative effort from families, schools, healthcare systems, and policymakers. Encouraging healthy eating habits, increasing opportunities for physical activity, improving access to affordable nutritious foods, and supporting preventive healthcare can all play a role in reducing obesity rates. While the statistics are serious, they also provide an opportunity to focus on meaningful solutions that can improve the health and well-being of future generations.

Your responses and feedback are welcome!

Source: “Childhood Obesity Facts,” CDC, 5/6/26
Source: “National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files development of files and prevalence estimates for selected health outcomes,” National Health Statistics Report, 2021
Source: “Association of body mass index with health care expenditures in the United States by age and sex,” PLOS One, 3/24/21
Image by U.S. Centers for Disease Control and Prevention, via Wikimedia Commons/Public Domain

GLP-1 Coverage Cuts by Medicaid

As demand for GLP-1 medications continues to surge across the United States, a growing number of states are reevaluating whether they can afford to cover these drugs for obesity treatment under Medicaid. Recent proposals in Massachusetts and Rhode Island highlight a broader national trend: balancing access to innovative but expensive therapies with the realities of state budgets.

A shrinking list of states offering coverage

Just a year ago, 16 state Medicaid programs covered GLP-1 medications specifically for weight loss. That number has now dropped to 13. States like California, New Hampshire, Pennsylvania, and South Carolina have already eliminated this benefit, citing unsustainable costs.

GLP-1 drugs, originally developed for diabetes management, have gained widespread attention for their effectiveness in promoting weight loss. However, their high price tag has made them a significant financial burden for publicly funded programs like Medicaid.

Proposed changes in Massachusetts and Rhode Island

In Massachusetts, Governor Maura Healey’s proposed fiscal 2028 budget would remove coverage of GLP-1 drugs for weight loss under MassHealth, the state’s Medicaid program. Importantly, coverage would remain intact for patients using these medications to treat diabetes or other medical conditions. The proposal is still under legislative review, leaving room for potential revisions.

Similarly, Rhode Island’s governor has proposed eliminating Medicaid coverage for GLP-1 medications when prescribed solely for obesity treatment. These decisions reflect a growing concern among policymakers: how to prioritize limited healthcare dollars while still addressing widespread chronic conditions.

Despite these cutbacks, several states continue to provide coverage for GLP-1 drugs for obesity. These include Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, Tennessee, Utah, Virginia, and Wisconsin.

However, even among these states, access is often limited. For example, Michigan has restricted eligibility to patients with morbid obesity, excluding those who are overweight or moderately obese. This policy adjustment alone is projected to save the state an estimated $240 million, illustrating the scale of financial pressure these medications create.

Louisiana’s ongoing debate

In Louisiana, lawmakers are considering a middle-ground approach. Rather than offering broad coverage, the state may allow Medicaid to cover GLP-1 medications for obesity only when patients also have a related chronic condition, such as prediabetes, hypertension, or cardiovascular disease.

This strategy aims to target patients at the highest risk while controlling costs, but it also raises questions about equity and early intervention. Should treatment be limited to those already experiencing complications, or should it be expanded to prevent them?

The cost challenge

The financial strain driving these decisions is substantial. Medicaid spending on GLP-1 prescriptions (covering both diabetes and weight loss) has skyrocketed from about $1 billion in 2019 to nearly $9 billion in 2024, according to KFF.

For those without insurance, affordability remains a major barrier. In response, Novo Nordisk announced plans to lower the list price of its GLP-1 medications to $675 per month by 2027. While this reduction may improve access, it is still a significant expense for many patients and for state-funded programs.

High need, limited access

The debate over GLP-1 coverage comes at a time when obesity rates remain high. Nearly 40% of adults and about 25% of children enrolled in Medicaid have obesity, suggesting a large population could potentially benefit from these medications. Yet, as states tighten coverage, a pattern emerges: Innovative treatments are becoming more effective and more popular, but not necessarily more accessible.

The kids are also affected

As Philadelphia’s WHYY reported, the Children’s Hospital of Philadelphia (CHOP) did some research about the coverage specifically for children:

CHOP researchers found that only a fraction of eligible kids ultimately get a GLP-1 prescription. Even after they do, families struggle with cost and insurance coverage issues that make it hard for their children to stay on the medication.

Side effects and gaps in follow-up care are also causing disruptions in medication use, according to CHOP’s findings, recently published in the journal Pediatrics.

Looking ahead

The future of GLP-1 coverage under Medicaid is far from settled. As more states weigh the costs and benefits, policies will likely continue to evolve, creating a patchwork system where access depends heavily on geography.

For patients, providers, and policymakers alike, the challenge is clear: how to expand access to life-changing treatments without overwhelming already stretched healthcare budgets. Whether through pricing reforms, eligibility adjustments, or alternative treatment strategies, the decisions made today will shape obesity care for years to come.

Your responses and feedback are welcome!

Source: “Philly pediatricians are using GLP-1 drugs to treat childhood obesity, but cost can be a major barrier, CHOP doctors find,” WHYY, 5/4/26
Source: “Only 13 States’s Medicaid Still Cover GLP-1 Drugs to Treat Obesity, and More Are Dropping Out,” FlaglerLive.com, 4/30/26
Source: “Rhode Island considers ending Medicaid coverage of GLP-1 drugs for weight loss,” Rhode Island Current, 6/10/25
Source: “Louisiana Medicaid might add coverage for popular obesity treatment drugs,” Louisiana Illuminator, 4/16/26
Source: “Medicaid Coverage of and Spending on GLP-1s,” KFF, 1/16/26
Image by SHVETS production/Pexels

What New Research Says About Childhood Growth and BMI

For decades, pediatric health experts have relied on a concept known as “adiposity rebound” to help assess a child’s future risk of obesity. Traditionally, this stage, when body mass index (BMI) begins to rise again after early childhood, has been viewed as a potential warning sign. But new research published in The Journal of Nutrition is challenging that long-held belief and offering a more nuanced understanding of how children grow.

A look at childhood growth patterns

The study analyzed data from 2,410 children and adolescents ages 2 to 19 who participated in the National Health and Nutrition Examination Survey (NHANES) between 2021 and 2023. Researchers observed a familiar trend: BMI decreases in early childhood, then begins to rise again around age 6 — the classic “adiposity rebound.”

However, there was a surprising twist. While BMI increased, another important measurement, the waist-to-height ratio, continued to decline. This metric is considered a more accurate indicator of body fat, particularly abdominal fat.

The implication? The rise in BMI during this stage may not signal increased fat at all. Instead, it may reflect healthy growth in lean tissues like muscle and bone.

Why BMI alone may be misleading

BMI has long been used as a simple screening tool because it relies on such basic measurements as height and weight. But it has a significant limitation, as it cannot distinguish between fat mass and fat-free mass. This distinction is especially important in children, whose bodies are constantly changing.

Lead researcher Andrew Agbaje emphasized this concern, saying:

Recent global consensus statements on redefining and diagnosing obesity have recommended that obesity should not be diagnosed with BMI alone but confirmed with non-invasive measures such as waist-to-height ratio.

He also said:

This new study buttresses the misleading use of BMI in children whose body composition rapidly changes during growth and the potential for attributing physiological functions to pathology, which might lead to unnecessary interventions. Waist-to-height ratio should be incorporated as the first inexpensive measure in diagnosing pediatric obesity with BMI used as a confirmatory tool due to its imprecision.

Introducing the “body composition reset”

One of the most compelling ideas to emerge from the study is what researchers call a “body composition reset.” This term describes the natural shift toward lean tissue development during early childhood. Rather than indicating a buildup of fat, the increase in BMI may actually reflect a healthy phase of growth, one that supports strength, bone development, and overall physical maturation. This finding challenges the assumption that an earlier adiposity rebound automatically signals a higher risk of obesity later in life.

Why waist-to-height ratio matters

Unlike BMI, the waist-to-height ratio focuses on fat distribution, particularly abdominal fat, which is more closely linked to health risks such as heart disease, Type 2 diabetes, high blood pressure, liver disease, and bone fractures. Because it is less influenced by muscle growth, this measurement provides a clearer picture of whether a child is carrying excess body fat.

A shift in pediatric obesity screening

The study adds to a growing body of evidence suggesting that BMI should not be used in isolation when evaluating children’s health. Incorporating waist-to-height ratio could help clinicians better distinguish between normal growth and true obesity risk, avoid unnecessary labeling or interventions, and provide more accurate, individualized care, among other things.

Recognition for innovative research

Agbaje’s contributions to pediatric cardiometabolic health have not gone unnoticed. He is the inaugural recipient of the American Society for Nutrition Foundation/Novo Nordisk Foundation Flemming Quaade Award, which honors early-career physicians making significant strides in obesity prevention and management. The award will be presented again at NUTRITION 2026, scheduled for July 25–28, 2026, in National Harbor, Maryland.

So, in a nutshell, a single number like BMI cannot tell the whole story. The new approach may reduce the chances of misclassifying healthy developmental changes as medical concerns. For parents, it should serve as a reassuring message that not every change in BMI signals a problem. Sometimes, it simply reflects a child growing exactly as they should.

Your responses and feedback are welcome!

Source: “Study Challenges Decades-Old Puzzle About Childhood Body Fat,” American Society for Nutrition, 4/23/26
Source: “Adiposity Rebound or Fat-Free Mass Anabolism in Children…,” The Journal of Nutrition, 3/9/26
Image by beyzahzah/Pexels

Genetics May Shape the Future of GLP-1 Medications

Childhood obesity treatment is entering a new and highly personalized era. As GLP-1 receptor agonists gain traction as effective tools for weight management in adolescents, emerging research suggests that genetics may play a key role in determining who benefits most (and who experiences side effects).

This evolving intersection of obesity medicine and precision health could transform how providers treat pediatric patients. But it also raises important questions about cost, access, and equity.

The rise of GLP-1 medications in pediatric care

GLP-1 (glucagon-like peptide-1) receptor agonists, including semaglutide and liraglutide, have rapidly become a cornerstone of modern obesity treatment. Originally developed for type 2 diabetes, these medications help regulate appetite, slow digestion, and improve blood sugar control. In adolescents with obesity, clinical trials have demonstrated significant reductions in body mass index (BMI), often far exceeding results from lifestyle interventions alone.

A major study published in The New England Journal of Medicine found that teens treated with semaglutide experienced an average 16% reduction in BMI over 68 weeks. These results have fueled growing adoption in pediatric care and prompted updated treatment guidelines from the American Academy of Pediatrics, which now include pharmacotherapy as part of comprehensive obesity management.

While GLP-1 medications have shown impressive results, not all patients respond the same way. Some adolescents lose significant weight, while others see more modest changes, or struggle with side effects like nausea and vomiting. Recent research highlights a possible explanation: genetic variation. Studies suggest that certain genetic differences may influence how the body regulates appetite and metabolism, how strongly GLP-1 receptors respond to medication, and the likelihood and severity of gastrointestinal side effects.

In fact, new findings reported by Reuters indicate that specific genetic markers may be linked to both greater weight loss outcomes and increased side effect risk in patients taking GLP-1 drugs. This opens the door to a more tailored approach, where treatment decisions are guided not just by BMI or medical history, but by a patient’s genetic profile.

What is personalized (precision) medicine?

Personalized medicine, also known as precision medicine, is an approach that uses individual factors like genetics, environment, and lifestyle to guide healthcare decisions. The National Institutes of Health defines precision medicine as a way to “optimize medical care by tailoring it to individual characteristics.”

In the context of pediatric obesity, this could mean identifying which children are most likely to benefit from GLP-1 medications, predicting who may experience side effects before treatment begins, and adjusting dosages or selecting alternative therapies based on genetic insights. This approach has the potential to make treatment more effective, safer, and more efficient.

Potential benefits for pediatric patients

If successfully implemented, genetically guided obesity treatment could offer several advantages:

1. Improved Outcomes. Children could receive medications that are more likely to work for their specific biology, increasing the chances of meaningful weight loss and improved health.
2. Reduced Trial-and-Error. Providers could avoid prescribing medications that are less likely to be effective, saving time and reducing frustration for families.
3. Better Side Effect Management. Identifying genetic risk factors for side effects may help clinicians proactively manage or avoid adverse reactions.
4. More Efficient Use of Healthcare Resources. Targeted treatment could reduce unnecessary costs associated with ineffective therapies.

Ethical and equity considerations

While the promise of personalized medicine is compelling, it also introduces new challenges, particularly around access and equity, such as cost barriers, a risk of widening disparities, and data privacy concerns. Genetic testing can be expensive, and insurance coverage is inconsistent. Combined with the already high cost of GLP-1 medications, this could limit access for many families.

Also, communities already disproportionately affected by childhood obesity, such as low-income and minority populations, may have the least access to advanced testing and treatments. And, the Centers for Disease Control and Prevention continues to report higher obesity rates among underserved populations, making equitable access a critical concern. Plus, genetic testing raises questions about how sensitive health data is stored, shared, and protected (especially for children).

The integration of genetics into pediatric obesity treatment represents a major step toward more individualized, science-driven care. However, experts emphasize that medication, personalized or not, should always be part of a broader, holistic approach.

As research continues, the key challenge will be ensuring that innovation does not outpace accessibility. Personalized treatment has the potential to improve outcomes, but only if it is available to all children who need it.

Your responses and feedback are welcome!

Source: “Once-Weekly Semaglutide in Adolescents with Obesity,” The New England Journal of Medicine, 11/2/22
Source: “Semaglutide Treatment Effect in People With Obesity — STEP TEENS,” American College of Cardiology, 12/20/22
Source: “Genetics may help explain why results from weight-loss jabs vary, say scientists,” The Guardian, 4/6/26
Source: “Researchers move closer to matching patients with GLP-1 drug that works best for them,” Reuters, 11/19/25
Source: “The Promise of Precision Medicine,” NIH, undated
Source: “New CDC Data Show Adult Obesity Prevalence Remains High,” CDC, 9/12/24
Image by Tara Winstead/Pexels

The Rise of GLP-1 Medications in Pediatric Obesity: Breakthrough or Barrier?

Childhood obesity remains one of the most urgent public health challenges in the United States, affecting roughly one in five children and adolescents. According to the Centers for Disease Control and Prevention, the prevalence of obesity among U.S. youth is about 19.7%, with higher rates among certain racial, ethnic, and low-income populations.

While lifestyle interventions, such as improved nutrition, increased physical activity, and behavioral counseling, have long been the foundation of treatment, a new class of medications is rapidly transforming the field: GLP-1 receptor agonists. These drugs are generating both excitement and debate, especially as their use expands into pediatric care.

So, are GLP-1 medications a true breakthrough, or do they risk widening existing gaps in care?

What are GLP-1 medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic a naturally-occurring hormone involved in regulating appetite, insulin secretion, and digestion. By slowing gastric emptying and increasing satiety, they help reduce food intake and promote weight loss.

Two of the most widely discussed GLP-1 medications are semaglutide and liraglutide. Originally approved for type 2 diabetes, both medications are now FDA-approved for chronic weight management in certain adolescent populations aged 12 and older. Their growing popularity reflects a broader shift toward recognizing obesity as a chronic, biologically complex disease, not simply a result of lifestyle choices.

Clinical trials have demonstrated significant results in adolescents using GLP-1 medications. A landmark study published in The New England Journal of Medicine found that teens treated with semaglutide experienced an average 16.1% reduction in BMI, compared to just 0.6% in the placebo group. Similarly, trials involving liraglutide showed meaningful reductions in BMI and improvements in metabolic health markers.

Beyond weight loss, GLP-1 medications may improve insulin resistance, blood pressure, and lipid profiles (cholesterol levels). These benefits are particularly important given that childhood obesity is strongly linked to long-term risks such as type 2 diabetes, cardiovascular disease, and even certain cancers.

Despite their clinical promise, GLP-1 medications remain out of reach for many families. Without insurance, these drugs can cost $900 to $1,300 per month, a significant financial burden. Even for insured patients, access is often delayed by prior authorization requirements, step therapy protocols, and inconsistent coverage policies.

According to the American Academy of Pediatrics, disparities in access to obesity treatment, including medications, mirror broader inequities in healthcare. Children from underserved communities, who are already at higher risk for obesity, are often the least likely to receive advanced treatments.

Additional barriers include limited availability of pediatric obesity specialists, geographic disparities in care access, and stigma surrounding obesity treatment. This raises a critical concern: Could a breakthrough therapy unintentionally widen health disparities?

While short-term outcomes are encouraging, long-term safety data in pediatric populations is still evolving.

Common side effects include nausea, vomiting, diarrhea, or constipation. In most cases, these symptoms are mild to moderate and improve over time. However, there are still unanswered questions about long-term use in developing bodies, potential impacts on growth and development, weight regain after discontinuation, and more.

Early evidence suggests that stopping GLP-1 therapy often leads to partial or full weight regain, highlighting the chronic nature of obesity and the potential need for ongoing treatment. Experts emphasize that medication should not replace foundational lifestyle interventions but instead serve as part of a comprehensive, multidisciplinary care plan.

The emergence of GLP-1 medications marks a turning point in pediatric obesity treatment. For adolescents who have struggled with traditional approaches, these therapies offer meaningful, evidence-based results, and in many cases, renewed hope. However, their full potential will only be realized if systemic barriers are addressed.

Expanding insurance coverage, improving provider access, and reducing stigma will be essential to ensuring equitable care. As research continues and policies evolve, the challenge is clear: How do we ensure that this medical breakthrough benefits all children, not just a select few?

Your responses and feedback are welcome!

Source: “Once-Weekly Semaglutide in Adolescents with Obesity,” The New England Journal of Medicine, 11/2/22
Source: “Prescriptions for Obesity Medications Among Adolescents Aged 12–17 Years with Obesity — United States, 2018–2023,” CDC, 6/5/25
Source: “Executive Summary: Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity,” Pediatrics, February 2023
Source: “New Institute for Clinical and Economic Review Report Shows Significant Jump in Launch Prices, Exceeding Inflation and GDP Growth,” ICER, 10/23/25
Image by Leeloo The First/Pexels